Success Story

Penn spinout Interius Biotherapeutics raises another $21.5M

Penn spinout Interius BioTherapeutics raised $21.5 million to advance its cancer-fighting technology platform.

Co-founded by Saar Gill, MD, PhD, Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania, Interius is developing a new platform for cell-specific gene delivery in patients.

Earlier this summer, Interius presented preclinical data showing the potential of its lead program, INT2104, to generate biologically active cancer-fighting CAR-T cells directly within the body, as opposed to the traditional method of bioengineering them in a lab. 

Since its inception in 2019, Interius has now raised nearly $100 million towards their development targeted gene delivery. 

Read more here.

Skip to content